Showing 711-720 of 1942 results for "".
FDA Approves First Treatment for MacTel
https://modernod.com/podcasts/eyewire-news-the-podcast/fda-approves-first-treatment-for-mactel/37075/The CEO of Neurotech joins us to talk about the FDA approval of the first treatment for MacTel; a target action date is set for Sydnexis’ pediatric myopia treatment candidate; and three eye care companies collaborate to launch a wearable vision testing platform. Learn more about your ad choices. VisHaag-Streit Launches METIS 900 Microscope
https://modernod.com/podcasts/eyewire-news-the-podcast/haag-streit-launches-metis-900-microscope/37074/Haag-Streit launches the METIS 900 ophthalmic microscope system; the FDA accepts Glaukos’ NDA for Epi-on cross-linking; and Optos releases its next generation ultra-widefield SLO imaging technology. Learn more about your ad choices. Visit megaphone.fm/adchoicesZeiss MEL 90 Approved by FDA
https://modernod.com/podcasts/eyewire-news-the-podcast/zeiss-mel-90-approved-by-fda/37068/Zeiss receives a major approval for its new excimer laser; Bausch + Lomb makes two deals to bolster its pipeline in glaucoma and geographic atrophy; and Rayner announces the full European launch of its RayOne Galaxy IOLs. Learn more about your ad choices. Visit megaphone.fm/adchoicesGlaukos Submits NDA for Epi-On CLX Candidate
https://modernod.com/podcasts/eyewire-news-the-podcast/glaukos-submits-nda-for-epi-on-clx-candidate/37066/Glaukos submits a new drug application to the FDA for its next-generation cross-linking therapy; Regeneron releases phase 3 results for Eylea HD for RVO; and Regeneron acquires a clinical stage biotech making ocular delivery technology for retinal disorders. Learn more about your ad choices. Visit mSpecial Report: OWL Celebrates 20th Anniversary
https://modernod.com/podcasts/eyewire-news-the-podcast/special-report-owl-celebrates-20th-anniversary/37060/Executives from Ophthalmic World Leaders discuss the history and goals of thee organization as it celebrates its 20th anniversary. Learn more about your ad choices. Visit megaphone.fm/adchoices68. Oh, the Places You’ll Go… as a New Grad ft. Dr. Alexa Hecht
https://modernod.com/podcasts/four-eyes/68-oh-the-places-youll-go-as-a-new-grad-ft-dr-alexa-hecht/37018/Amrit and Deepon sit down with Dr. Alexa Hecht, a new grad Optometrist from the University of Waterloo School of Optometry, to talk about her journey into practicing. Alexa shares the ups and downs of working in multiple practice locations six days a week, and how this work-life “imbalance” took a tIntroducing Premium Products and Services to Patients
https://modernod.com/topics/business/introducing-premium-products-and-services-to-patients/38553/Advice to make you feel more confident about offering this important aspect of clinical care.Genetic Testing: What It Is, How It Works, and More
https://modernod.com/podcasts/the-mod-pod/genetic-testing-what-it-is-how-it-works-and-more/36836/Sumit (Sam) Garg, MD, and Brandon Ayres, MD, discuss how they use AvaGen™, The Genetic Eye Test, to inform patients about their genetic risk of developing keratoconus and other corneal dystrophies, and the role it plays in helping them decide appropriate treatment.Alcon Acquires Staar for $1.5 Billion
https://modernod.com/podcasts/eyewire-news-the-podcast/alcon-acquires-staar-for-15-billion/37096/Alcon makes a major acquisition to expand its refractive portfolio; the CEO of Lenz Therapeutics joins us to discuss the FDA approval of a new presbyopia drop; and the optical industry braces for major changes as new reciprocal tariffs are set to begin this week. Learn more about your ad choices.Alcon Acquires LumiThera
https://modernod.com/podcasts/eyewire-news-the-podcast/alcon-acquires-lumithera/37092/Alcon makes a major acquisition to bolster is vitreoretinal surgery portfolio; the European Commission (EC) approves Eylea 8 mg for extended treatment intervals; and Eric Donnenfeld, MD, discusses the business of myopia management. Learn more about your ad choices. Visit megaphone.fm/adchoices